Breaking News Instant updates and real-time market news.

AMRN

Amarin

$18.87

-0.46 (-2.38%)

08:08
03/20/19
03/20
08:08
03/20/19
08:08

STAT Expert Advantage to hold a teleconference

Teleconference entitled, "Digging into Amarin's REDUCE-IT Data" discusses Amarin's March 18th presentation on their fish oil drug, Vascepa, at the American College of Cardiology's 68th Annual Scientific Session, will be held on March 20 at 12 pm.

  • 20

    Mar

  • 25

    Mar

AMRN Amarin
$18.87

-0.46 (-2.38%)

01/31/19
CANT
01/31/19
NO CHANGE
Target $35
CANT
Overweight
Cantor reiterates $35 target on Amarin after surveying 50 physicians
After surveying 50 physicians regarding Vascepa, Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Amarin with a $35 price target. The stock closed yesterday up 48c to $16.94. The analyst says the survey results underscore her belief that the market opportunity is underappreciated. 52% of physicians noted the high triglyceride patients they see have cardiovascular risk factors beyond what can be mitigated by cholesterol management, Chen tells investors in a research note. She believes the Reduce-It study positions Vascepa to be the first drug to cost-effectively help address CV risk beyond cholesterol management. Chen expects an acceleration in the uptake of Vascepa in 2019.
02/01/19
PIPR
02/01/19
NO CHANGE
PIPR
Overweight
Amgen acquisition of Alexion could make a lot of sense, says Piper Jaffray
While most investors anticipate Amgen (AMGN) could be shopping for smaller, bolt-on deals amid increased investor and press speculation that it is now an active acquirer, a larger deal with more near-term accretion potential may make more sense, Piper Jaffray analyst Christopher Raymond tells investors in a research note partially titled "Go Big or Go Home?" He thinks a potential Amgen for Alexion Pharmaceuticals (ALXN) deal "could actually make a lot of sense." Even at levels approaching $200 per share for Alexion, Amgen "could make a strong argument for a business combination," says Raymond. Alexion closed yesterday up $1.64 to $122.96. The analyst admits that some "bolt-on deals have been bandied around" by investors that "arguably make sense" for Amgen, including Biohaven Pharmaceutical and Amarin (AMRN). However, none of these options on their own get Amgen "to where they need to be to address the growth challenges of the legacy franchises," Raymond argues. He thinks a better deal for the company may be Alexion, which would bring in a "long-tailed asset" with Soliris/Ultomiris, an area Amgen has already approached with its Soliris biosimilar effort. The analyst's math has the potential deal being accretive next year, growing to 20%-plus accretion by 2024 for Amgen, even at a takeout price approaching $200 per Alexion share. Raymond keeps Overweight ratings on both companies.
02/28/19
HCWC
02/28/19
NO CHANGE
Target $51
HCWC
Buy
Amarin offered window into Vascepa revenue momentum, says H.C. Wainwright
On yesterday's call, Amarin shared a few data points of Vascepa's growth post Reduce-IT results that offered a glimpse of the revenue momentum, and "may be a forbearer of what is to come," H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst highlights the 32%-33% prescription increase in the Q4 compared to the same period in 2017. Further, he expects Amarin to promote Vascepa with a greater degree of freedom that should further accelerate the adoption. Fein reiterates a Buy rating on Amarin with a $51 price target.
03/13/19
SBSH
03/13/19
NO CHANGE
SBSH
Amarin's Reduce-It results viewed favorably by doctors, says Citi
Citi analyst Joel Beatty conducted a survey of 325 U.S. physicians to assess views related to Amarin's Vascepa. Of the doctors that were "very familiar" with the Reduce-It results, 84% provided positive comments regarding the study, Beatty tells investors in a research note. Further, prior authorization requirements are seen as a "major barrier" to Vascepa use, the analyst adds. He keeps a Buy rating on Amarin.

TODAY'S FREE FLY STORIES

TGT

Target

$110.86

0.27 (0.24%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Breaking Hot Stocks news story on Target »

Target up 8.3% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AVY

Avery Dennison

$131.42

0.26 (0.20%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Avery Dennison to acquire Smartrac's RFID Inlay business for EUR225M »

Avery Dennison announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Earnings
Breaking Earnings news story on Target »

Target raises FY19 adj…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ADSK

Autodesk

$164.53

2.08 (1.28%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Recommendations
Autodesk analyst commentary  »

Autodesk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:36
11/20/19
11/20
06:36
11/20/19
06:36
Earnings
Qiwi raises FY19 adjusted revenue growth view to 15%-19% from 9%-15% »

Consensus for FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

TGT

Target

$110.86

0.27 (0.24%)

06:35
11/20/19
11/20
06:35
11/20/19
06:35
Earnings
Target sees Q4 adj. EPS $1.54-$1.75, consensus $1.65 

Sees Q4 SSS up 3%-4%.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$60.66

1.12 (1.88%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
TJX analyst commentary  »

Nomura Instinet lists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

T

AT&T

$38.00

-1.61 (-4.06%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
AT&T analyst commentary  »

KeyBanc data shows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

LLY

Eli Lilly

$115.13

1.04 (0.91%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Hot Stocks
Eli Lilly to invest $400M in Indianapolis manufacturing facilities »

Eli Lilly announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 30

    Jan

TGT

Target

$110.86

0.27 (0.24%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Target reports Q3 adj. EPS $1.36, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CDXC

ChromaDex

$3.49

0.19 (5.76%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Hot Stocks
ChromaDex: EC votes in favor on Nicotinamide Riboside Chloride as a novel food »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Qiwi reports Q3 EPS 29c, one estimate 33c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:29
11/20/19
11/20
06:29
11/20/19
06:29
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

06:26
11/20/19
11/20
06:26
11/20/19
06:26
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.63

-0.295 (-4.98%)

06:24
11/20/19
11/20
06:24
11/20/19
06:24
Downgrade
Qudian rating change  »

Qudian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:22
11/20/19
11/20
06:22
11/20/19
06:22
Periodicals
WeWork began layoffs on Monday, Business Insider reports »

WeWork's layoffs…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Downgrade
Berry Petroleum rating change  »

Wells Fargo downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBCP

Concrete Pumping

$3.88

0.17 (4.58%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Conference/Events
Concrete Pumping management to meet with William Blair »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.03

-1.85 (-10.96%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Periodicals
Macy's confirms 'targeted data security incident' impacted customers, WSJ says »

Macy's says customer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AL

Air Lease

$45.16

0.435 (0.97%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Conference/Events
Air Lease management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Downgrade
Berry Petroleum rating change  »

KeyBanc downgrades Berry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XGN

Exagen

$19.25

-0.04 (-0.21%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Conference/Events
Exagen management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

WWW

Wolverine World Wide

$32.86

-0.61 (-1.82%)

06:17
11/20/19
11/20
06:17
11/20/19
06:17
Conference/Events
Wolverine World Wide management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 02

    Dec

GM

General Motors

$36.39

-0.23 (-0.63%)

06:17
11/20/19
11/20
06:17
11/20/19
06:17
Periodicals
GM not liable for punitive damages in ignition switch cases, Reuters reports »

General Motors is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.